Blister Packaging Medication to Increase Treatment Adherence and Clinical Response (BP)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01118208|
Recruitment Status : Completed
First Posted : May 6, 2010
Last Update Posted : October 20, 2017
|Condition or disease||Intervention/treatment||Phase|
|Medication Adherence Accidental Overdose Deliberate Overdose Suicide, Attempted||Other: Blister packaging medications Other: Dispense as usual||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||303 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Single (Outcomes Assessor)|
|Official Title:||Blister Packaging Medication to Increase Treatment Adherence and Clinical Response: Impact on Suicide-Related Morbidity and Mortality|
|Study Start Date :||September 2009|
|Actual Primary Completion Date :||June 2014|
|Actual Study Completion Date :||September 2014|
Experimental: Blister Packaging
Patients will receive all prescription medications on blister pack cards.
Other: Blister packaging medications
Dispensing prescription medications on pre-filled blister package cards.
Other Name: Blister cards, bubble packs, unit-dose packaging.
Active Comparator: Dispense as Usual
Patients will receive all prescription medications in standard pill bottles.
Other: Dispense as usual
Dispensing prescription medications in standard pill bottles.
- Medication Adherence as assessed with the Brief Adherence Rating Scale (BARS) [ Time Frame: monthly for 12 months ]
- Medication overdoses as measured by the Self-Harm Behavior Questionnaire (SHBQ) [ Time Frame: monthly for 12 months ]Both accidental and intentional overdoses will be assessed.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01118208
|United States, Colorado|
|Denver VA Medical Center|
|Denver, Colorado, United States, 80220|
|Principal Investigator:||Peter M Gutierrez, Ph.D.||VA VISN 19 MIRECC|